845546-62-5

Basic information

• Product Name: (2R,4R)-2-[(1S,2S)-2-amino-3-(3,5-difluorophenyl)-1-hydroxypropyl]-4-benzyloxypyrrolidine-1-carboxylic acid tert-butyl ester
• Synonyms: (2R,4R)-2-[(1S,2S)-2-amino-3-(3,5-difluorophenyl)-1-hydroxypropyl]-4-benzyloxypyrrolidine-1-carboxylic acid tert-butyl ester
• CAS NO: 845546-62-5
• Molecular Weight: 462.537
• Mol File: 845546-62-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (2R,4R)-2-[(1S,2S)-2-amino-3-(3,5-difluorophenyl)-1-hydroxypropyl]-4-benzyloxypyrrolidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,4R)-2-[(1S,2S)-2-amino-3-(3,5-difluorophenyl)-1-hydroxypropyl]-4-benzyloxypyrrolidine-1-carboxylic acid tert-butyl ester(845546-62-5)
• EPA Substance Registry System: (2R,4R)-2-[(1S,2S)-2-amino-3-(3,5-difluorophenyl)-1-hydroxypropyl]-4-benzyloxypyrrolidine-1-carboxylic acid tert-butyl ester(845546-62-5)

Safety Data

• Hazardous Substances Data: 845546-62-5(Hazardous Substances Data)

Upstream product

• 869527-83-3 tert-butyl (2R,4R)-4-benzyloxy-2-[(1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-2-nitropropyl]pyrrolidine-1-carboxylate 
• 845972-73-8 C₂₆H₃₀F₂N₂O₅ 

Relevant articles and documents

BETA-SECRETASE INHIBITING COMPOUNDS HAVING OXO-DIHYDRO-PYRAZOLE MOIETY

Disclosed are compounds represented by Formula (I) as defined in the specification, or pharmaceutically acceptable salts or isomers thereof, and a pharmaceutical composition for inhibiting beta-secretase activity comprising a therapeutically effective amo

BACE INHIBITORS

The present invention provides BACE inhibitors of Formula (I): methods for their use and preparation, and intermediates for their preparation.

CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R is-C(O)-N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer’s disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, and N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.